Coronado Initiates Phase 1/2 Dose Escalation Trial of Allogeneic Natural Killer Cells Activated by CNDO-109

Coronado Biosciences CNDO, a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of a phase 1/2 dose escalation trial of allogeneic natural killer (NK) cells activated by the Company's CNDO-109 in patients in first complete remission (CR1) from acute myeloid leukemia (AML), and who are deemed high-risk for relapse. "Over 70% of AML patients who achieve a first complete remission will relapse, and it remains a significant unmet medical need. In an investigator-initiated phase 1 trial reported late last year, a number of patients experienced a longer complete remission after receiving CNDO-109 activated NK cells than their previous complete remission, so we are pleased to advance the clinical development of this novel immunotherapy," said Dr. Bobby W. Sandage, Jr., Coronado's President and CEO. "Earlier this year, we received Orphan Drug Designation from the FDA for CNDO-109 for the treatment of AML and we were recently granted our first U.S. patent covering CNDO-109." The phase 1/2 trial is a multi-center, open-label, single-dose, dose-escalating clinical study designed to examine the safety of CNDO-109 activated allogeneic NK cells, as well See full press release